Direct Flow Medical Transcatheter Aortic Valve System image courtesy of Direct Flow Medical
March 30, 2016 — Direct Flow Medical Inc. announced European commercial market launch of the DirecTrack Delivery System, a next-generation delivery system for the Direct Flow Medical Transcatheter Aortic Valve System.
According to the company, the Direct Flow Medical system is the only non-metallic, conformable transcatheter aortic valve that can be functionally assessed, repositioned, and retrieved prior to final implant.
The next-generation DirecTrack Delivery System features advanced ergonomic design and functionality to provide physicians with greater procedural control during valve implantation. “I have had the opportunity to use every generation of the Direct Flow Medical delivery system since its inception. The new DirecTrack system is a major step forward in positioning control and smooth valve delivery,” stated Joachim Schofer, M.D., professor of cardiology, Hamburg University Cardiovascular Center, Hamburg. He continued, “I’m impressed with the additional procedural efficiency gained, making it faster and easier to achieve an optimal outcome.”
Direct Flow Medical is sponsoring the SALUS Pivotal Trial in the United States to investigate the Direct Flow Medical Transcatheter Aortic Valve System for treatment of high- and extreme-risk severe symptomatic aortic stenosis. The system is commercially available in Europe for treatment of patients with aortic stenosis who are at extreme surgical risk.
For more information: www.directflowmedical.com
July 31, 2024 
